Streetbeat News

Analyst Ratings

INVH

Evercore ISI Group analyst Steve Sakwa has upgraded Invitation Homes (NYSE:INVH) from In-Line to Outperform and set a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:59 pm

NVDA

NVIDIA's stock is trading higher after Goldman Sachs added the company to its Conviction List, indicating a strong buy recommendation.

Portfolio Pulse from Bill Haddad

October 02, 2023 | 1:50 pm

UTZ

Piper Sandler analyst Michael Lavery has maintained an Overweight rating on Utz Brands (NYSE:UTZ), but lowered the price target from $22 to $17.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:49 pm

TMP

Piper Sandler analyst Alexander Twerdahl has maintained a Neutral rating on Tompkins Financial (AMEX:TMP) and raised the price target from $50 to $52.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:47 pm

NFLX

A significant amount of unusual options activity has been observed for Netflix (NASDAQ:NFLX), with a majority of investors taking a bullish stance. The price range targeted by these investors over the last three months is between $370 and $500. However, expert opinions vary, with price targets ranging from $293 to $500. The current price of NFLX is $377.08, down by 0.14%, and the next earnings are expected in 16 days.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 1:46 pm

ASML

A significant investor has taken a bearish stance on ASML Holding (NASDAQ:ASML), with 90% of recent trades reflecting bearish expectations. The trades include 5 puts totaling $224,660 and 5 calls totaling $193,610. The targeted price range for ASML Holding over the last 3 months is $520.0 to $650.0. The current price of ASML is down -0.89% at $583.42, and RSI indicators suggest the stock may be oversold.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 1:46 pm

DMTTF

PSIL

The article discusses recent developments in the field of psychedelic therapies for mental health disorders. Small Pharma's (OTC:DMTTF) Phase 1b study on DMT and SSRIs for major depressive disorder (MDD) has released new findings. TheraPsil, a Canadian non-profit, has launched an MDMA-assisted psychotherapy training program. Apex Labs' psilocybin macrodose drug protocol has been approved for a Canadian veteran's treatment-resistant depression. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has been on a slow downtrend. Other companies mentioned include GH Research (NASDAQ:GHRS), COMPASS Pathways (NASDAQ:CMPS), Mind Medicine (NASDAQ:MNMD), Enveric Biosciences (NASDAQ:ENVB), Bright Minds Biosciences (NASDAQ:DRUG), Silo Pharma (NASDAQ:SILO), Atai Life Sciences (NASDAQ:ATAI), FSD Pharma (NASDAQ:HUGE), Incannex Healthcare (NASDAQ:IXHL), Lucy Scientific Discovery (NASDAQ:LSDI), and Cybin Inc. (NYSE:CYBN).

Portfolio Pulse from Lara Goldstein

October 02, 2023 | 1:46 pm

AIZ

Piper Sandler analyst John Barnidge maintains an Overweight rating on Assurant (NYSE:AIZ) and raises the price target from $150 to $165.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:39 pm

VST

BMO Capital analyst James Thalacker has maintained an Outperform rating on Vistra (NYSE:VST) and raised the price target from $40 to $42.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:29 pm

MG

MISTRAS Group, Inc. (MG: NYSE) has announced the implementation of the first Project Phoenix initiative, a reorganization of the Company's Products & Systems segment expected to increase Adjusted EBITDA by $4.0 Million in Fiscal 2024. The company also announced the appointment of Gennaro (Jerry) D'Alterio as Executive Vice President and Chief Commercial Officer. These initiatives are part of the company's strategy to accelerate the transition into faster growing markets and improve the performance of its traditional energy-related market operations.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:16 pm